Alaunos Therapeutics logo
Alaunos Therapeutics
TCRT | NASDAQ
Chart Builder DCF Calculator
$1.62
-$0.01 (-0.61%)
At close: Nov 16, 2026, 3:59 PM ET
$1.56
-$0.06 (-3.70%)
After-hours: Nov 16, 2026, 7:30 PM ET

Alaunos Therapeutics Company Profile

Company profile explained

Company Profile

Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.

Key Executives

Name Position
Holger Weis Chairman of the Board & Chief Executive Officer
Ferdinand Groenewald Vice President of Finance & Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 23, 2026 8-K Current Report
Oct 21, 2026 8-K Current Report
Oct 15, 2026 SC 13D/A [Amend] Filing
Oct 15, 2026 3 Filing
Oct 15, 2026 SC 13D Filing
Oct 13, 2026 8-K Current Report
Oct 09, 2026 8-K Current Report
Oct 08, 2026 4 Filing
Oct 08, 2026 4 Filing
Oct 08, 2026 4 Filing
View All SEC Filings ➞
Alaunos Therapeutics
Alaunos Therapeutics logo
Country United States
IPO Date Aug 24, 2005
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Holger Weis

Contact Details

501 E. Las Olas Blvd. Fort Lauderdale, Florida 33301 United States

Stock Details

Ticker Symbol TCRT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001107421
CUSIP Number 98973P309
ISIN Number US98973P3091
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.